1
|
González-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I, Barragán-Cárdenas AC, Ramírez-Celis DA, Martínez-Ramírez JA, Fierro-Medina R, García-Castañeda JE, Rivera-Monroy ZJ. In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides. Biomed Chromatogr 2023; 37:e5741. [PMID: 37688464 DOI: 10.1002/bmc.5741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 08/15/2023] [Accepted: 08/23/2023] [Indexed: 09/11/2023]
Abstract
Matrix effect and sample pretreatment significantly affect the percentage recovery of peptides in biological matrices, affecting the method robustness and accuracy. To counteract this effect, an internal standard (IS) is used; however, in most cases this is not available, which limits the analytical method. It is important to identify short peptides that can be used as ISs in the quantification of peptides in biological matrices. In this study, doping peptides GHRP-4, GHRP-5, GHRP-6, Sermorelin (1-11), Sermorelin (13-20) and Sermorelin (22-29) were synthesized using solid-phase peptide synthesis. Treatment with human blood, trypsin and chymotrypsin was used to determine the stability of the peptides. Products were evaluated using the high-performance liquid chromatography-diode array detector (HPLC-DAD) method. The analytical methodology and sample pretreatment were effective for the analysis of these molecules. A unique profile related to protein binding and enzymatic stability of each peptide was established. GHRP-4, GHRP-6 and Sermorelin (22-29) can be considered as in-house ISs as they were stable to enzyme and blood treatment and can be used for the quantification of peptides in biological samples. Peptides GHRP-6 and Sermorelin (22-29) were used to analyse a dimeric peptide (26 [F] LfcinB (20-30)2 ) in four different matrices to test these peptides as in-house IS.
Collapse
|
2
|
Insuasty-Cepeda DS, Barragán-Cárdenas AC, Ardila-Chantre N, Cárdenas-Martínez KJ, Rincón-Quiñones I, Vargas-Casanova Y, Ochoa-Zarzosa A, Lopez-Meza JE, Parra-Giraldo CM, Ospina-Giraldo LF, Fierro-Medina R, García-Castañeda JE, Rivera-Monroy ZJ. Non-natural amino acids into LfcinB-derived peptides: effect in their (i) proteolytic degradation and (ii) cytotoxic activity against cancer cells. ROYAL SOCIETY OPEN SCIENCE 2023; 10:221493. [PMID: 37325596 PMCID: PMC10265003 DOI: 10.1098/rsos.221493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 04/21/2023] [Indexed: 06/17/2023]
Abstract
The dimeric peptide 26[F]: (RRWQWRFKKLG)2-K-Ahx has exhibited a potent cytotoxic effect against breast cancer cell lines, with position 26 (F) being the most relevant for anti-cancer activity. In this investigation, six analogues of the 26[F] peptide were synthesized in which the 26th position was replaced by non-natural hydrophobic amino acids, finding that some modifications increased the resistance to proteolytic degradation exerted by trypsin or pepsin. Additionally, these modifications increased the cytotoxic effect against breast cancer cells and generated cell death mediated by apoptosis pathways, activating caspases 8 and 9, and did not compromise the integrity of the cytoplasmic membrane. Finally, it was found that the modified peptides have a broad spectrum of action, since they also have a cytotoxic effect against the HeLa human cervical cancer cell line. Peptide 26[F] was inoculated in mice by ip administration and the lethal dose 50 (LD50) was between 70 and 140 mg kg-1. While for the 26[1-Nal]: (RRWQWR-1-Nal-KKLG)2-K-Ahx peptide, a dose-response test was performed, and the survival rate was 100%. These results suggested that these peptides are safe in this animal model and could be considered as promissory to develop a treatment against breast cancer.
Collapse
Affiliation(s)
- Diego Sebastián Insuasty-Cepeda
- Chemistry Department, Universidad Nacional de Colombia, Bogotá, Carrera 45 No 26-85, Building 451, office 409, Bogotá 11321, Colombia
| | | | - Natalia Ardila-Chantre
- Pharmacy Department, Universidad Nacional de Colombia, Bogotá, Carrera 45 No 26-85, Building 450, Bogotá 11321, Colombia
| | | | - Isabella Rincón-Quiñones
- Pharmacy Department, Universidad Nacional de Colombia, Bogotá, Carrera 45 No 26-85, Building 450, Bogotá 11321, Colombia
| | - Yerly Vargas-Casanova
- Microbiology deparment, Pontificia Universidad Javeriana, Bogotá, Carrera 7 No 40-62, Building 450, Bogotá 11321, Colombia
| | - Alejandra Ochoa-Zarzosa
- Multidisciplinary Centre for Studies in Biotechnology, Universidad Michoacana de San Nicolas de Hidalgo, Km 9.5, Morelia, Mexico
| | - Joel Edmundo Lopez-Meza
- Multidisciplinary Centre for Studies in Biotechnology, Universidad Michoacana de San Nicolas de Hidalgo, Km 9.5, Morelia, Mexico
| | - Claudia Marcela Parra-Giraldo
- Microbiology deparment, Pontificia Universidad Javeriana, Bogotá, Carrera 7 No 40-62, Building 450, Bogotá 11321, Colombia
| | - Luis Fernando Ospina-Giraldo
- Pharmacy Department, Universidad Nacional de Colombia, Bogotá, Carrera 45 No 26-85, Building 450, Bogotá 11321, Colombia
| | - Ricardo Fierro-Medina
- Chemistry Department, Universidad Nacional de Colombia, Bogotá, Carrera 45 No 26-85, Building 451, office 409, Bogotá 11321, Colombia
| | | | - Zuly Jenny Rivera-Monroy
- Chemistry Department, Universidad Nacional de Colombia, Bogotá, Carrera 45 No 26-85, Building 451, office 409, Bogotá 11321, Colombia
| |
Collapse
|
3
|
González-López N, Insuasty-Cepeda DS, Huertas-Ortiz KA, Reyes-Calderón JE, Martínez-Ramírez JA, Fierro-Medina R, Jenny Rivera-Monroy Z, García-Castañeda JE. Gradient Retention Factor Concept Applied to Method Development for Peptide Analysis by Means of RP-HPLC. ACS OMEGA 2022; 7:44817-44824. [PMID: 36530233 PMCID: PMC9753532 DOI: 10.1021/acsomega.2c04907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Accepted: 10/05/2022] [Indexed: 06/17/2023]
Abstract
Using the van Deemter model, the efficiency of three stationary phase systems in the analysis of a mixture of synthetic peptides was evaluated: (i) monolithic, (ii) packed, and (iii) core-shell columns, and it was shown that the efficiency of the monolithic column is superior to the others, specifically using it, the lowest values of H min (0.03 and 0.1 mm) were obtained, and additionally its efficiency was not significantly affected by increasing the flow. Using the concept of the gradient retention factor (k*), a method for chromatographic separation of a peptide complex mixture was designed, implemented, and optimized and then transferred from a packed column to a monolithic one. The results showed that it was possible to separate all components of the mixture using both evaluated columns; moreover, the analysis time was reduced from 70 to 10 min, conserving the critical pair resolution (1.4), by the transfer method using the k* concept. The method developed was tested against a mixture of doping peptides, showing that this method is efficient for separating peptides of various natures. This investigation is very useful for the development of methods for the analysis of complex peptide mixtures since it provides a systematic approach that can be extrapolated to different types of columns and instrumentation.
Collapse
Affiliation(s)
- Nicolás
Mateo González-López
- Pharmacy
Department, Universidad Nacional de Colombia,
Bogotá, Carrera
45 No 26-85, Building 450, 11321Bogotá, Colombia
| | | | - Kevin Andrey Huertas-Ortiz
- Chemistry
Department, Universidad Nacional de Colombia,
Bogotá, Carrera 45 No 26-85, Building 451, 11321Bogotá, Colombia
| | - Juan Esteban Reyes-Calderón
- Chemistry
Department, Universidad Nacional de Colombia,
Bogotá, Carrera 45 No 26-85, Building 451, 11321Bogotá, Colombia
| | - Jorge Ariel Martínez-Ramírez
- Pharmacy
Department, Universidad Nacional de Colombia,
Bogotá, Carrera
45 No 26-85, Building 450, 11321Bogotá, Colombia
| | - Ricardo Fierro-Medina
- Chemistry
Department, Universidad Nacional de Colombia,
Bogotá, Carrera 45 No 26-85, Building 451, 11321Bogotá, Colombia
| | - Zuly Jenny Rivera-Monroy
- Chemistry
Department, Universidad Nacional de Colombia,
Bogotá, Carrera 45 No 26-85, Building 451, 11321Bogotá, Colombia
| | | |
Collapse
|
4
|
Barragán-Cárdenas AC, Insuasty-Cepeda DS, Cárdenas-Martínez KJ, López-Meza J, Ochoa-Zarzosa A, Umaña-Pérez A, Rivera-Monroy ZJ, García-Castañeda JE. LfcinB-Derived Peptides: Specific and punctual change of an amino acid in monomeric and dimeric sequences increase selective cytotoxicity in colon cancer cell lines. ARAB J CHEM 2022. [DOI: 10.1016/j.arabjc.2022.103998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022] Open
|
5
|
Martínez-Villaluenga C, Hernández-Ledesma B. Peptides for Health Benefits 2020. Int J Mol Sci 2022; 23:ijms23126699. [PMID: 35743143 PMCID: PMC9223426 DOI: 10.3390/ijms23126699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 06/09/2022] [Indexed: 11/28/2022] Open
Affiliation(s)
| | - Blanca Hernández-Ledesma
- Institute of Food Science Research (CIAL, CSIC-UAM, CEI UAM + CSIC), Nicolás Cabrera 9, 28049 Madrid, Spain
- Correspondence:
| |
Collapse
|
6
|
Overview of Host Defense Peptides with Promising Anti-Breast Cancer Activity. SERBIAN JOURNAL OF EXPERIMENTAL AND CLINICAL RESEARCH 2022. [DOI: 10.2478/sjecr-2021-0052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
Breast cancer is the leading cause of death among women worldwide. The main limitations of conventional anti-cancer therapy, including breast cancer treatment, are side effects and the development of resistance to chemotherapeutics. Host defense peptides (HDPs) are bioactive compounds of innate immunity isolated from almost all living organisms, which exhibit wide range of biological activities. This review focuses on the anti-cancer effects of HDPs and their therapeutic potential against breast cancer. Numerous HDPs from different sources, including mammalian and amphibian origin, and their chemically modified analogues, exert the spectrum of anti-cancer activities. These effects include direct disruption of cancer cell membrane, induction of apoptosis, inhibition of angiogenesis and cancer cell proliferation, but also the modulation of anti-cancer immune response. Selected examples of HDPs of different origin and their anti-breast cancer capacities have been reviewed. Conclusively, due to their anti-cancer effects accompanied by substantial selectivity for cancer cells and low toxicity for normal cells, HDPs have been widely recognized as possible therapeutic agents.
Collapse
|
7
|
Vitale I, Yamazaki T, Wennerberg E, Sveinbjørnsson B, Rekdal Ø, Demaria S, Galluzzi L. Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides. Trends Cancer 2021; 7:557-572. [PMID: 33446447 DOI: 10.1016/j.trecan.2020.12.012] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 12/09/2020] [Accepted: 12/15/2020] [Indexed: 02/07/2023]
Abstract
Accumulating preclinical and clinical evidence indicates that high degrees of heterogeneity among malignant cells constitute a considerable obstacle to the success of cancer therapy. This calls for the development of approaches that operate - or enable established treatments to operate - despite such intratumoral heterogeneity (ITH). In this context, oncolytic peptides stand out as promising therapeutic tools based on their ability to drive immunogenic cell death associated with robust anticancer immune responses independently of ITH. We review the main molecular and immunological pathways engaged by oncolytic peptides, and discuss potential approaches to combine these agents with modern immunotherapeutics in support of superior tumor-targeting immunity and efficacy in patients with cancer.
Collapse
Affiliation(s)
- Ilio Vitale
- Italian Institute for Genomic Medicine (IIGM), Istituto Di Ricovero e Cura a Carattere Scientifico (IRCSS) Candiolo, Torino, Italy; Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-IRCCS, Candiolo, Italy
| | - Takahiro Yamazaki
- Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
| | - Erik Wennerberg
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
| | - Baldur Sveinbjørnsson
- Lytix Biopharma, Oslo, Norway; Department of Medical Biology, University of Tromsø, Tromsø, Norway; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden
| | - Øystein Rekdal
- Lytix Biopharma, Oslo, Norway; Department of Medical Biology, University of Tromsø, Tromsø, Norway
| | - Sandra Demaria
- Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA
| | - Lorenzo Galluzzi
- Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; Université de Paris, Paris, France.
| |
Collapse
|